National Medical Products Administration: By 2030, initially establish an integrated innovation system combining drug regulation and artificial intelligence

Mars Finance News April 2, the National Medical Products Administration released the “Implementation Opinions on ‘Artificial Intelligence + Drug Regulation’.” Among other points, it proposes that by 2030, an integrated innovation system combining drug regulation and artificial intelligence will be initially established; the operating and management mechanism for “artificial intelligence + drug regulation” will be basically formed; the computing power support base will be more intensive and efficient; high-quality datasets, vertical large models, and intelligent agents will be developed to meet the needs of intelligent drug regulation; artificial intelligence will be effectively applied in scenarios such as review and approval, supervision and inspections, testing and monitoring, and government services; the efficiency of human-machine collaboration will be significantly improved; and drug regulation capabilities with digital and intelligent coverage across the entire lifecycle will reach a new level. By 2035, a new smart framework for drug safety governance driven by digital intelligence, featuring intelligent agility, self-controllability, and ecosystem-wide coordination will basically be formed. (National Medical Products Administration)